246 related articles for article (PubMed ID: 30540167)
1. Distinct Binding Characteristics of Pathogenic Anti-Platelet Factor-4/Polyanion Antibodies to Antigens Coated on Different Substrates: A Perspective on Clinical Application.
Nguyen TH; Greinacher A
ACS Nano; 2018 Dec; 12(12):12030-12041. PubMed ID: 30540167
[TBL] [Abstract][Full Text] [Related]
2. Characterization of New Monoclonal PF4-Specific Antibodies as Useful Tools for Studies on Typical and Autoimmune Heparin-Induced Thrombocytopenia.
Vayne C; Nguyen TH; Rollin J; Charuel N; Poupon A; Pouplard C; Normann N; Gruel Y; Greinacher A
Thromb Haemost; 2021 Mar; 121(3):322-331. PubMed ID: 33086397
[TBL] [Abstract][Full Text] [Related]
3. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.
Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726
[TBL] [Abstract][Full Text] [Related]
4. Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity.
Nguyen TH; Medvedev N; Delcea M; Greinacher A
Nat Commun; 2017 May; 8():14945. PubMed ID: 28530237
[TBL] [Abstract][Full Text] [Related]
5. Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.
Litvinov RI; Yarovoi SV; Rauova L; Barsegov V; Sachais BS; Rux AH; Hinds JL; Arepally GM; Cines DB; Weisel JW
J Biol Chem; 2013 Nov; 288(46):33060-70. PubMed ID: 24097975
[TBL] [Abstract][Full Text] [Related]
6. Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia.
Huynh A; Arnold DM; Kelton JG; Smith JW; Horsewood P; Clare R; Guarné A; Nazy I
J Thromb Haemost; 2019 Feb; 17(2):389-399. PubMed ID: 30582672
[TBL] [Abstract][Full Text] [Related]
7. Testing for heparin-induced thrombocytopenia antibodies.
Warkentin TE; Sheppard JA
Transfus Med Rev; 2006 Oct; 20(4):259-72. PubMed ID: 17008164
[TBL] [Abstract][Full Text] [Related]
8. Reactivity of platelet-activating and nonplatelet-activating anti-PF4/heparin antibodies in enzyme immunosorbent assays under different conditions.
Nguyen TH; Wesche J; Raschke R; Strobel U; Bui VC; Delcea M; Greinacher A
J Thromb Haemost; 2019 Jul; 17(7):1113-1119. PubMed ID: 31009154
[TBL] [Abstract][Full Text] [Related]
9. Effect of pH and ionic strength on the binding strength of anti-PF4/polyanion antibodies.
Nguyen TH; Greinacher A
Eur Biophys J; 2017 Dec; 46(8):795-801. PubMed ID: 28712066
[TBL] [Abstract][Full Text] [Related]
10. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium.
Pouplard C; Amiral J; Borg JY; Vissac AM; Delahousse B; Gruel Y
Br J Haematol; 1997 Nov; 99(2):273-80. PubMed ID: 9375738
[TBL] [Abstract][Full Text] [Related]
11. 5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.
Kizlik-Masson C; Vayne C; McKenzie SE; Poupon A; Zhou Y; Champier G; Pouplard C; Gruel Y; Rollin J
J Thromb Haemost; 2017 Oct; 15(10):2065-2075. PubMed ID: 28771917
[TBL] [Abstract][Full Text] [Related]
12. The epitope specificity of heparin-induced thrombocytopenia.
Horsewood P; Warkentin TE; Hayward CP; Kelton JG
Br J Haematol; 1996 Oct; 95(1):161-7. PubMed ID: 8857955
[TBL] [Abstract][Full Text] [Related]
13. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.
Krauel K; Hackbarth C; Fürll B; Greinacher A
Blood; 2012 Feb; 119(5):1248-55. PubMed ID: 22049520
[TBL] [Abstract][Full Text] [Related]
14. Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT.
Krauel K; Preuße P; Warkentin TE; Trabhardt C; Brandt S; Jensch I; Mandelkow M; Hammer E; Hammerschmidt S; Greinacher A
Blood; 2019 Feb; 133(9):978-989. PubMed ID: 30573633
[TBL] [Abstract][Full Text] [Related]
15. Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia.
Nazy I; Clare R; Staibano P; Warkentin TE; Larché M; Moore JC; Smith JW; Whitlock RP; Kelton JG; Arnold DM
J Thromb Haemost; 2018 Jul; 16(7):1402-1412. PubMed ID: 29723924
[TBL] [Abstract][Full Text] [Related]
16. Heparin-induced thrombocytopenia: frequency and pathogenesis.
Greinacher A
Pathophysiol Haemost Thromb; 2006; 35(1-2):37-45. PubMed ID: 16855345
[TBL] [Abstract][Full Text] [Related]
17. [Platelet factor 4, target of anti-heparin antibodies: application to biological diagnosis of heparin-induced thrombopenia].
Amiral J
Ann Med Interne (Paris); 1997; 148(2):142-9. PubMed ID: 9238439
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity.
Brandt S; Krauel K; Gottschalk KE; Renné T; Helm CA; Greinacher A; Block S
Thromb Haemost; 2014 Jul; 112(1):53-64. PubMed ID: 24671506
[TBL] [Abstract][Full Text] [Related]
19. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia.
Krauel K; Pötschke C; Weber C; Kessler W; Fürll B; Ittermann T; Maier S; Hammerschmidt S; Bröker BM; Greinacher A
Blood; 2011 Jan; 117(4):1370-8. PubMed ID: 20959601
[TBL] [Abstract][Full Text] [Related]
20. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation.
Amiral J; Pouplard C; Vissac AM; Walenga JM; Jeske W; Gruel Y
Br J Haematol; 2000 May; 109(2):336-41. PubMed ID: 10848821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
